Improve clinical decision-making and patient outcomes with biomarkers
The well-established biomarkers, Thermo Scientific™ B·R·A·H·M·S PCT™ (Procalcitonin) and Thermo Scientific™ B·R·A·H·M·S MR-proADM™ (Mid-regional proADrenoMedullin), can play a crucial role in promptly identifying sepsis infection and improving patient prognosis. These biomarkers can be invaluable to healthcare professionals in emergency departments and intensive care units, as they can significantly impact clinical decision-making and patient management. By facilitating early detection of infections, they contribute to improved patient outcomes while minimising unnecessary treatments and reducing healthcare costs. When determining the most suitable antibiotic treatment for a patient, clinicians rely on accurate and reliable data. With its sensitivity and specificity in identifying bacterial infections, combined with its fast kinetics, Thermo Scientific B·R·A·H·M·S PCT stands apart from other biomarkers.
Informational: This product is not available for purchase by the general public
Established early sepsis detection
B·R·A·H·M·S Procalcitonin (PCT)
Thermo Scientific B·R·A·H·M·S PCT is a trusted and preferred biomarker due to its high sensitivity to detect the presence or absence of bacterial infection.
B·R·A·H·M·S PCT has been in use for over 25 years and is established as an effective procalcitonin for differential diagnosis, sepsis severity assessment, prognosis of bacterial infection, and antibiotic stewardship.
Disease severity assessment in emergency and intensive care departments
B·R·A·H·M·S MR-proADM
Mid-regional proadrenomedullin (MR-proADM) is a blood biomarker that is elevated in diseased states in response to the increased hyper-permeability of the microcirculation and subsequent plasma leakage into the extracellular space. In addition, adrenomedullin has potent vasodilatory properties.
It can be used in both the emergency and intensive care departments to assess the severity of an infection on the host response and the risk of disease progression.
Use in the emergency department
The use of these biomarkers in the emergency department (ED) can decrease the time to treatment, increase the number of outpatients, and reduce the length of stay. Study: MR-proADM in the ED: Early identification of disease progression to sepsis
Use in the intensive care unit
The utilisation of these biomarkers in the intensive care unit (ICU) can maximise patient safety, guide the administration of the most suitable treatment, and provide an early warning of potential additional complications. Study: Sepsis in the ICU: Sepsis severity and progression
Resources
The availability of products may vary in each country depending on local regulatory requirements.
Contact your local specialist for more details